Agilent attributes its success in part to a “Build and Buy” approach that combines internal growth with external acquisitions—$2.9 billion in mergers and acquisitions since FY 2015—as well as capital investment, dividends and share repurchases. For FY 2022, Agilent has issued guidance to investors projecting between $6.65 billion and $6.73 billion, with year-over-year core revenue growth of between five and a half and seven percent . . .

- Agilent Technologies
- Therapeutics
- Biologics
- Bioprocessing
- Cell Analysis
- China
- Molecular Diagnostics/In vitro Diagnostics
- Companion Diagnostics
- OMICs
- DNA
- Drug Discovery
- GEN Edge
- Lab Equipment
- Oligonucleotides
- Small Molecules
Agilent CEO: “We’re Not Just a One-Year Wonder!”
In Part 1 of an exclusive interview with GEN Edge, Agilent CEO Mike McMullen discusses how pharma and biotech sets the pace for company’s strong growth
Agilent’s quality control lab for oligonucleotide production in Frederick, CO. Since 2019, Agilent has expanded its commercial-scale manufacturing of oligos, a significant driver of company growth in recent years. [Agilent Technologies]